abbvie-dermatologie-daten-aad-2026 - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,839 +0.83%

DJIA 48,339 +0.90%

Nasdaq 25,091 +0.79%

DAX 23,928 -0.15%

Gold $4,196 +0.16%

Oil $95.75 -0.97%

BTC $72,426 +1.48%

VIX 20.43 -15.85%

EUR/USD 1.1785 -0.02%

ETH $2,222 +0.59%

S&P 500 6,839 +0.83%

DJIA 48,339 +0.90%

Nasdaq 25,091 +0.79%

DAX 23,928 -0.15%

Gold $4,196 +0.16%

Oil $95.75 -0.97%

BTC $72,426 +1.48%

VIX 20.43 -15.85%

EUR/USD 1.1785 -0.02%

ETH $2,222 +0.59%

abbvie-dermatologie-daten-aad-2026

AbbVie Dermatology Data spotlight Skyrizi and Rinvoq dermatology treatments in premium product focus

Pharma & Healthcare·Stocks·USA

AbbVie Dermatology Data Boom at AAD 2026 Shocks Investors

By Maik Kemper • Mar 27, 2026

AbbVie Dermatology Data spotlight Skyrizi and Rinvoq dermatology treatments in premium product focus

Pharma & Healthcare·Stocks·USA

AbbVie Dermatology Data Boom at AAD 2026 Shocks Investors

By Maik Kemper • Mar 27, 2026

Can AbbVie’s latest dermatology data at AAD 2026 really secure its post-Humira growth story in immunology? Maik Kemper Editor in Chief Our robust evidence across…